{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:32:59Z","timestamp":1791822779819,"version":"4.3.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s10557-017-6723-4","type":"journal-article","created":{"date-parts":[[2017,4,18]],"date-time":"2017-04-18T06:19:08Z","timestamp":1492496348000},"page":"179-186","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":124,"title":["The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): Revision for Clinical Use, Content Validation, and Inter-rater Reliability"],"prefix":"10.1007","volume":"31","author":[{"given":"Robert S","family":"Rosenson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Bayliss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie T","family":"Baccara-Dinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Chibedi-De-Roche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irfan","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garen","family":"Manvelian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry A.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,18]]},"reference":[{"issue":"17","key":"6723_CR1","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1001\/jama.2015.13766","volume":"314","author":"ED Kantor","year":"2015","unstructured":"Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. Trends in prescription drug use among adults in the United States from 1999-2012. JAMA. 2015;314(17):1818\u201331.","journal-title":"JAMA"},{"issue":"3 Suppl","key":"6723_CR2","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jacl.2014.03.004","volume":"8","author":"RS Rosenson","year":"2014","unstructured":"Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA. The National Lipid Association\u2019s muscle safety expert panel an assessment by the statin muscle safety task force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S58\u201371.","journal-title":"J Clin Lipidol."},{"issue":"5","key":"6723_CR3","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jacl.2013.03.001","volume":"7","author":"MY Wei","year":"2013","unstructured":"Wei MY, Ito MK, Cohen JD, Brinton EA, Jacobson TA. Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. J Clin Lipidol. 2013;7(5):472\u201383.","journal-title":"J Clin Lipidol."},{"issue":"10059","key":"6723_CR4","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","volume":"388","author":"R Collins","year":"2016","unstructured":"Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532\u201361.","journal-title":"Lancet"},{"issue":"9841","key":"6723_CR5","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","volume":"380","author":"B Mihaylova","year":"2012","unstructured":"Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581\u201390.","journal-title":"Lancet"},{"key":"6723_CR6","unstructured":"Graham JH, Sanchez RJ, Saseen JJ, Mallya UG, Panaccio MP, Evans MA. Clinical and economic consequences of statin intolerance in the United States: results from an integrated health system. J Clin Lipidol. 2016."},{"key":"6723_CR7","doi-asserted-by":"crossref","unstructured":"Serban MC, Colantonio LD, Mathripragada AD, Monda KL, Bittner VA, Banach M, Chen L, Huang L, Dent R, Kent ST, Muntner P, Rosenson RS. Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction. J Am Coll Cardiol. 2017;69(11);1386\u201395.","DOI":"10.1016\/j.jacc.2016.12.036"},{"issue":"3","key":"6723_CR8","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/MOL.0000000000000174","volume":"26","author":"BA Taylor","year":"2015","unstructured":"Taylor BA, Thompson PD. Muscle-related side-effects of statins: from mechanisms to evidence-based solutions. Curr Opin Lipidol. 2015;26(3):221\u20137.","journal-title":"Curr Opin Lipidol"},{"issue":"10","key":"6723_CR9","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.mayocp.2015.08.014","volume":"90","author":"BA Franklin","year":"2015","unstructured":"Franklin BA, Lavie CJ. Impact of statins on physical activity and fitness: ally or adversary? Mayo Clin Proc. 2015;90(10):1314\u20139.","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"6723_CR10","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1037\/0033-2909.86.2.420","volume":"86","author":"PE Shrout","year":"1979","unstructured":"Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979;86(2):420\u20138.","journal-title":"Psychol Bull"},{"issue":"9","key":"6723_CR11","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/sim.1108","volume":"21","author":"DG Bonett","year":"2002","unstructured":"Bonett DG. Sample size requirements for estimating intraclass correlations with desired precision. Stat Med. 2002;21(9):1331\u20135.","journal-title":"Stat Med"},{"issue":"1","key":"6723_CR12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jclinepi.2006.03.012","volume":"60","author":"CB Terwee","year":"2007","unstructured":"Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, et al. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol. 2007;60(1):34\u201342.","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"6723_CR13","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","volume":"9","author":"PM Moriarty","year":"2015","unstructured":"Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015;9(6):758\u201369.","journal-title":"J Clin Lipidol."},{"issue":"15","key":"6723_CR14","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","volume":"315","author":"SE Nissen","year":"2016","unstructured":"Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA. 2016;315(15):1580\u201390.","journal-title":"JAMA"},{"issue":"4","key":"6723_CR15","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jacl.2016.05.002","volume":"10","author":"JA Tobert","year":"2016","unstructured":"Tobert JA, Newman CB. The nocebo effect in the context of statin intolerance. J Clin Lipidol. 2016;10(4):739\u201347.","journal-title":"J Clin Lipidol"},{"issue":"6","key":"6723_CR16","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.jval.2016.03.1858","volume":"19","author":"KL Schulman","year":"2016","unstructured":"Schulman KL, Lamerato LE, Dalal MR, Sung J, Jhaveri M, Koren A, et al. Development and validation of algorithms to identify statin intolerance in a US administrative database. Value Health. 2016;19(6):852\u201360.","journal-title":"Value Health"},{"issue":"5","key":"6723_CR17","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s10557-016-6680-3","volume":"30","author":"LD Colantonio","year":"2016","unstructured":"Colantonio LD, Kent ST, Huang L, Chen L, Monda KL, Serban MC, et al. Algorithms to identify statin intolerance in Medicare administrative claim data. Cardiovasc Drugs Ther. 2016;30(5):525\u201333.","journal-title":"Cardiovasc Drugs Ther"},{"key":"6723_CR18","doi-asserted-by":"crossref","unstructured":"Jacobson TA, Edelman SV, Galipeau N, Shields AL, Mallya UG, Koren A, et al. Development and content validity of the Statin Experience Assessment Questionnaire (SEAQ) (c). Patient. 2016.","DOI":"10.1007\/s40271-016-0211-y"},{"issue":"1","key":"6723_CR19","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/CIRCULATIONAHA.112.136101","volume":"127","author":"BA Parker","year":"2013","unstructured":"Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J, et al. Effect of statins on skeletal muscle function. Circulation. 2013;127(1):96\u2013103.","journal-title":"Circulation"},{"issue":"2","key":"6723_CR20","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.atherosclerosis.2014.12.016","volume":"238","author":"BA Taylor","year":"2015","unstructured":"Taylor BA, Lorson L, White CM, Thompson PD. A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis. 2015;238(2):329\u201335.","journal-title":"Atherosclerosis"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-017-6723-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-017-6723-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-017-6723-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,21]],"date-time":"2019-09-21T04:57:43Z","timestamp":1569041863000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-017-6723-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["6723"],"URL":"https:\/\/doi.org\/10.1007\/s10557-017-6723-4","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4]]}}}